Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Vertex Pharmaceuticals
Vertex Pharmaceuticals
Vertex gets in on GPCR game, paying Septerna $47M for undisclosed program
Vertex gets in on GPCR game, paying Septerna $47M for undisclosed program
Fierce Biotech
Vertex Pharmaceuticals
GPCRs
Septerna
Flag link:
Promising Vertex Pain Med Points to New Era for Analgesics
Promising Vertex Pain Med Points to New Era for Analgesics
BioSpace
Vertex Pharmaceuticals
VX-548
NEJM
painkillers
post-surgical pain
Flag link:
Aiming to be biggest biotech in Boston, Vertex plots 500-person cell, gene therapy R&D center
Aiming to be biggest biotech in Boston, Vertex plots 500-person cell, gene therapy R&D center
Fierce Biotech
Vertex Pharmaceuticals
cell therapy
gene therapy
R&D
Boston
Flag link:
First-ever CRISPR-CAS9 therapy, exa-cel, shows promising results
First-ever CRISPR-CAS9 therapy, exa-cel, shows promising results
Clinical Trials Arena
Vertex Pharmaceuticals
exa-cel
CRISPR
beta thalassemia
Flag link:
Vertex Pharma raises full-year revenue forecast on cystic fibrosis treatment strength
Vertex Pharma raises full-year revenue forecast on cystic fibrosis treatment strength
Yahoo/Reuters
Vertex Pharmaceuticals
cystic fibrosis
earnings
Flag link:
U.S. watchdog lifts price estimate for Bluebird, Vertex/CRISPR gene therapies to $2.1 million
U.S. watchdog lifts price estimate for Bluebird, Vertex/CRISPR gene therapies to $2.1 million
Reuters
ICER
gene therapy
Vertex Pharmaceuticals
CRISPR Therapeutics
Bluebird Bio
drug pricing
sickle cell disease
Flag link:
10 clinical trials to watch in the second half of 2023
10 clinical trials to watch in the second half of 2023
BioPharma Dive
FDA
clinical trials
Sarepta Therapeutics
Bridge Bio
Sanofi
Merck KGaA
Pfizer
Novo Nordisk
Verve Therapeutics
Roche
Vertex Pharmaceuticals
JNJ
Bristol Myers Squibb
ATTR-CM
Elevidys
tolebrutinib
evobrutinib
danuglipron
tiragolumab
VX-548
lazertinib
Flag link:
Gene Editing Race Between Editas and Vertex, CRISPR Heats Up
Gene Editing Race Between Editas and Vertex, CRISPR Heats Up
BioSpace
gene editing
Editas Medicine
Vertex Pharmaceuticals
CRISPR Therapeutics
EDIT-301
sickle cell disease
beta thalassemia
Flag link:
Landmark approval for Vertex's CRISPR drug 2 steps closer after trial wins, PDUFA date granted
Landmark approval for Vertex's CRISPR drug 2 steps closer after trial wins, PDUFA date granted
Fierce Biotech
Vertex Pharmaceuticals
CRISPR Therapeutics
CRISPR
gene editing
FDA
sickle cell disease
beta thalassemia
Flag link:
ReCode, Vertex and 4DMT Seek to Help Untreated Cystic Fibrosis Patients
ReCode, Vertex and 4DMT Seek to Help Untreated Cystic Fibrosis Patients
BioSpace
cystic fibrosis
ReCode
Vertex Pharmaceuticals
4DMT
Flag link:
2023’s biggest launches: the story so far
2023’s biggest launches: the story so far
EP Vantage
drug launches
AbbVie
Almirall
Apellis Pharmaceuticals
Astellas
AstraZeneca
Biogen
CRISPR Therapeutics
Daiichi Sankyo
Eli Lilly
Genmab
GSK
Iveric Bio
Pfizer
Roche
SAGE Therapeutics
Sanofi
Sarepta Therapeutics
Shionogi
Swedish Orphan Biovitrum
Vertex Pharmaceuticals
Flag link:
This FDA Nod Is a Game Changer for Patients: Could It Equal Billions for Vertex Pharmaceuticals?
This FDA Nod Is a Game Changer for Patients: Could It Equal Billions for Vertex Pharmaceuticals?
Motley Fool
Vertex Pharmaceuticals
cystic fibrosis
Kalydeco
infants
Flag link:
Finding the big spenders beyond big pharma
Finding the big spenders beyond big pharma
EP Vantage
R&D
Amgen
Bayer
Biogen
Gilead Sciences
Merck KGaA
Moderna Therapeutics
Novo Nordisk
Regeneron Pharmaceuticals
UCB
Vertex Pharmaceuticals
Flag link:
Big pharma holds steady on research spending
Big pharma holds steady on research spending
EP Vantage
R&D
AbbVie
Amgen
AstraZeneca
Bayer
Biogen
Bristol Myers Squibb
Eli Lilly
Gilead Sciences
GSK
JNJ
Merck
Merck KGaA
Moderna Therapeutics
Novartis
Novo Nordisk
Pfizer
Regeneron
Roche
Sanofi
UCB
Vertex Pharmaceuticals
Flag link:
Could This Move Make Vertex's Next Blockbuster Even Bigger?
Could This Move Make Vertex's Next Blockbuster Even Bigger?
Motley Fool
Vertex Pharmaceuticals
exa-cel
beta thalassemia
sickle cell disease
Flag link:
Gene Editing Therapeutics Could Hit the Market in 2023
Gene Editing Therapeutics Could Hit the Market in 2023
BioSpace
gene editing
CRISPR Therapeutics
Vertex Pharmaceuticals
Intellia Therapeutics
Editas Medicine
Beam Therapeutics
Flag link:
Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
Yahoo/Businesswire
Vertex Pharmaceuticals
CRISPR Therapeutics
sickle cell disease
beta thalassemia
FDA
exa-cel
Flag link:
Go or no go? Seagen's Padcev eyes FDA approval
Go or no go? Seagen's Padcev eyes FDA approval
EP Vantage
FDA
AbbVie
Alvotech
Ascendis Pharma
Astellas
AstraZeneca
Biogen
Daiichi Sankyo
Eli Lilly
Ferring Pharmaceuticals
Hugel
Innoviva
Ionis Pharmaceuticals
Lundbeck
Merck
Novo Nordisk
Otsuka
Pfizer
Roche Seagen
Seres Therapeutics
Takeda
UCB
Vertex Pharmaceuticals
Flag link:
Vertex ponies up $100M for CRISPR's gene editing tech to develop new diabetes modality
Vertex ponies up $100M for CRISPR's gene editing tech to develop new diabetes modality
Endpoints
Vertex Pharmaceuticals
diabetes
CRISPR
gene editing
CRISPR Therapeutics
Flag link:
Vertex flexes its dealmaking muscle
Vertex flexes its dealmaking muscle
EP Vantage
Vertex Pharmaceuticals
Entrada Therapeutics
Tevard Biosciences
Duchenne Muscular Dystrophy
Flag link:
Pages
1
2
3
4
5
6
7
8
9
…
next ›
last »